Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022

  • ID: 4376286
  • Report
  • Region: Global
  • 206 Pages
  • Markets and Markets
1 of 6
The Vaccines Market is Expected to Reach USD 49.27 Billion by 2022 from USD 32.31 Billion in 2016 at a CAGR of 7.5%.

FEATURED COMPANIES

  • Astellas Pharma, Inc.
  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • MORE

“Global vaccines market projected to grow at a CAGR of 7.5%”

Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development and product recalls.

“Conjugate vaccines are expected to dominate the market during the forecast period.”

By technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate segment is expected to hold the largest share of the market in 2017 and is also projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government investments are the key factors driving the growth of this segment.

“Monovalent vaccines segment expected to hold the largest share of the market in 2017.”

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.

“Pneumococcal disease segment is expected to witness high growth during the forecast period”

Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share and is projected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal disease.

“Asia to witness high growth during the forecast period”

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 36%; Tier 2 - 41%; Tier 3 - 23%.
  • By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
  • By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
  • By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Sanofi Pasteur SA
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • Johnson & Johnson
  • MedImmune, LLC
  • Astellas Pharma Inc.
  • Serum Institute of India
  • Bavarian Nordic
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company, Limited
  • Protein Science Corporation
  • Panacea Biotec

Research Coverage:

The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Astellas Pharma, Inc.
  • Bavarian Nordic
  • CSL Limited
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders

2 Research Methodology
2.1 Secondary Data
2.2 Primary Data
2.3 Key Industry Insights
2.4 Market Size Estimation
2.5 Market Breakdown And Data Triangulation
2.6 Market Share Estimation
2.7 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Overview of Global Vaccines Market
4.2 Global Vaccines Market, By Type, 2017-2022
4.3 Global Vaccines Market, By End-User, 2017 Vs. 2022 (USD Billion)
4.4 Geographic Analysis: Vaccines Market, By Technology
4.5 Global Vaccines Market, By Route of Administration, 2017 Vs. 2022 (USD Billion)
4.6 Geographical Snapshot of Global Vaccines Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus On Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Investments Into Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.2.2 Product Recalls
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus On Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.5 Burning Issues
5.2.5.1 Vaccine Pricing

6 Industry Insights
6.1 Investment Analysis
6.2 Regulatory Landscape
6.2.1 North America
6.2.2 Europe
6.2.3 Asia
6.2.4 Row
6.3 Key Pipeline Products
6.4 New Vaccine Opportunities
6.4.1 Hiv
6.4.1.1 Hiv Vaccine: Product Pipeline
6.4.1.2 Hiv Vaccine: Public-Private Initiatives
6.4.1.3 Hiv Vaccine: Funding
6.4.2 Malaria
6.4.2.1 Malaria Vaccine: Product Pipeline
6.4.2.2 Malaria Vaccine: Public-Private Initiatives
6.4.3 Zika
6.4.3.1 Zika Vaccine: Product Pipeline
6.4.3.2 Zika Vaccine: Public-Private Initiatives
6.4.3.3 Zika Vaccine: Funding
6.4.4 Ebola
6.4.4.1 Ebola Vaccine: Product Pipeline
6.4.4.2 Ebola Vaccine: Public-Private Initiatives
6.4.4.3 Ebola Vaccine: Funding
 
7 Global Vaccines Market, By Technology
7.1 Introduction
7.2 Conjugate Vaccines
7.3 Inactivated And Subunit Vaccines
7.4 Live Attenuated Vaccines
7.5 Recombinant Vaccines
7.6 Toxoid Vaccines

8 Global Vaccines Market, By Type
8.1 Introduction
8.2 Monovalent Vaccines
8.3 Multivalent Vaccines

9 Global Vaccines Market, By Disease Indication
9.1 Introduction
9.2 Pneumococcal Disease
9.3 Dtp
9.4 Influenza
9.5 Hpv
9.6 Meningococcal Disease
9.7 Polio
9.8 Rotavirus
9.9 Hepatitis
9.10 Mmr
9.11 Varicella
9.12 Dengue
9.13 Other Disease Indications

10 Global Vaccines Market, By Route of Administration
10.1 Introduction
10.2 Intramuscular And Subcutaneous Administration
10.3 Oral Administration
10.4 Other Routes of Administration

11 Global Vaccines Market, By End-User
11.1 Introduction
11.2 Pediatrics
11.3 Adults
 
12 Global Vaccines Market, By Region
12.1 Introduction
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 Roe
12.4 Asia
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Roa
12.5 Row

13 Competitive Landscape
13.1 Introduction
13.2 Market Share Analysis
13.3 Competitive Leadership Mapping
13.3.1 Visionary Leaders
13.3.2 Innovators
13.3.3 Dynamic Differentiators
13.3.4 Emerging Companies
13.4 Strength of Product Portfolio (For 25 Players)
13.5 Business Strategy Excellence (For 25 Players)
*Top 25 Companies Analyzed for this Studies Are - Pfizer, Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur Sa, Csl Limited, Emergent Biosolutions, Inc., Johnson & Johnson, Medimmune, Llc, Astellas Pharma Inc., Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Science Corporation, Daiichi Sankyo Company, Limited, Abbott Laboratories, Panacea Biotec, Paxvax, Inc., Zydus Cadila, Green Cross Corporation, Valneva Se, Indian Immunologicals Limited, Incepta Vaccine Ltd., Sinovac Biotech Ltd., Vbi Vaccines Inc., Pt Bio Farma (Persero)
 
14 Company Profiles
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
14.1 Pfizer, Inc.
14.2 Glaxosmithkline Plc.
14.3 Merck & Co., Inc.
14.4 Sanofi Pasteur Sa
14.5 Csl Limited
14.6 Emergent Biosolutions, Inc.
14.7 Johnson & Johnson
14.8 Medimmune, Llc (A Subsidiary of Astrazeneca)
14.9 Astellas Pharma, Inc.
14.10 Serum Institute of India
14.11 Bavarian Nordic
14.12 Mitsubishi Tanabe Pharma Corporation
14.13 Daiichi Sankyo Company, Limited
14.14 Protein Sciences Corporation
14.15 Panacea Biotec
*Details On View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, And Recent Developments Might Not Be Captured in Case of Unlisted Companies.

15 Appendix
15.1 Insights of Industry Experts
15.2 Discussion Guide
15.3 Knowledge Store: Subscription Portal
15.4 Introducing Rt: Real-Time Market Intelligence
15.5 Available Customizations
15.6 Related Reports
15.7 Author Details

List of Tables
Table 1 Incidence of Diseases, 2015
Table 2 Nih Funding for Vaccine Research, 2012-2017 (USD Million)
Table 3 Immunization Coverage, By Disease, 2014 Vs 2015
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Estimated Investments in Hiv Vaccines, By Investor (2015-2016)
Table 8 Ebola Projects Funded By Ec (2014-2020)
Table 9 Global Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 10 Cost of Meningococcal Conjugate Vaccines
Table 11 Global Conjugate Vaccines Market, By Region, 2015-2022 (USD Million)
Table 12 Examples of Inactivated And Subunit Vaccines
Table 13 Global Inactivated And Subunit Vaccines Market, By Region, 2015-2022 (USD Million)
Table 14 Global Live Attenuated Vaccines Market, By Region, 2015-2022 (USD Million)
Table 15 Examples of Recombinant Vaccines
Table 16 Global Recombinant Vaccines Market, By Region, 2015-2022 (USD Million)
Table 17 Global Toxoid Vaccines Market, By Region, 2015-2022 (USD Million)
Table 18 Global Vaccines Market, By Type, 2015-2022 (USD Million)
Table 19 Global Monovalent Vaccines Market, By Region, 2015-2022 (USD Million)
Table 20 Examples of Notable Multivalent Vaccines Available in the Market
Table 21 Global Multivalent Vaccines Market, By Region, 2015-2022 (USD Million)
Table 22 Global Vaccines Market, By Disease Indication, 2015-2022 (USD Million)
Table 23 List of Commercially Available Pneumococcal Vaccines in the Market
Table 24 Global Vaccines Market for Pneumococcal Disease, By Region, 2015-2022 (USD Million)
Table 25 List of Commercially Available Dtp Vaccines in the Market
Table 26 Global Vaccines Market for Dtp, By Region, 2015-2022 (USD Million)
Table 27 List of Commercially Available Influenza Vaccines in the Market
Table 28 Global Vaccines Market for Influenza, By Region, 2015-2022 (USD Million)
Table 29 List of Commercially Available Hpv Vaccines in the Market
Table 30 Global Vaccines Market for Hpv, By Region, 2015-2022 (USD Million)
Table 31 List of Commercially Available Hpv Vaccines in the Market
Table 32 Global Vaccines Market for Meningococcal Disease, By Region, 2015-2022 (USD Million)
Table 33 List of Commercially Available Polio Vaccines in the Market
Table 34 Global Vaccines Market for Polio, By Region, 2015-2022 (USD Million)
Table 35 List of Commercially Available Rotavirus Vaccines in the Market
Table 36 Global Vaccines Market for Rotavirus, By Region, 2015-2022 (USD Million)
Table 37 List of Commercially Available Hepatitis Vaccines in the Market
Table 38 Global Vaccines Market for Hepatitis, By Region, 2015-2022 (USD Million)
Table 39 List of Commercially Available Mmr Vaccines in the Market
Table 40 Global Vaccines Market for Mmr, By Region, 2015-2022 (USD Million)
Table 41 List of Commercially Available Varicella Vaccines in the Market
Table 42 Global Vaccines Market for Varicella, By Region, 2015-2022 (USD Million)
Table 43 List of Commercially Available Vaccines for Other Disease Indications in the Market
Table 44 Global Vaccines Market for Other Disease Indications, By Region, 2015-2022 (USD Million)
Table 45 Global Vaccines Market, By Route of Administration, 2015-2022 (USD Million)
Table 46 Global Vaccines Market for Intramuscular And Subcutaneous Administration, By Region, 2015-2022 (USD Million)
Table 47 Global Vaccines Market for Oral Administration, By Region, 2015-2022 (USD Million)
Table 48 Global Vaccines Market for Other Routes of Administration, By Region, 2015-2022 (USD Million)
Table 49 Global Vaccines Market Size, By End-User, 2015-2022 (USD Million)
Table 50 Global Pediatric Vaccines Market, By Region, 2015-2022 (USD Million)
Table 51 North America: Pediatric Vaccines Market, By Country, 2015-2022 (USD Million)
Table 52 Global Adult Vaccines Market, By Region, 2015-2022 (USD Million)
Table 53 North America: Adult Vaccines Market, By Country, 2015-2022 (USD Million)
Table 54 Global Vaccines Market, By Region, 2015-2022 (USD Million)
Table 55 North America: Vaccines Market, By Country, 2015-2022 (USD Million)
Table 56 North America: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 57 North America: Vaccines Market, By Type, 2015-2022 (USD Million)
Table 58 North America: Vaccines Market, By Disease Indication, 2015-2022 (USD Million)
Table 59 North America: Vaccines Market, By Route of Administration, 2015-2022 (USD Million)
Table 60 North America: Vaccines Market, By End-User, 2015-2022 (USD Million)
Table 61 U.S.: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 62 U.S.: Vaccines Market, By End-User, 2015-2022 (USD Million)
Table 63 Canada: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 64 Canada: Vaccines Market, By End-User, 2015-2022 (USD Million)
Table 65 Europe: Vaccines Market, By Country, 2015-2022 (USD Million)
Table 66 Europe: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 67 Europe: Vaccines Market, By Type, 2015-2022 (USD Million)
Table 68 Europe: Vaccines Market, By Disease Indication, 2015-2022 (USD Million)
Table 69 Europe: Vaccines Market, By Route of Administration, 2015-2022 (USD Million)
Table 70 Europe: Vaccines Market, By End-User, 2015-2022 (USD Million)
Table 71 Germany: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 72 U.K.: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 73 France: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 74 Italy: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 75 Spain: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 76 Roe: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 77 Asia: Health Expenditure Per Capita, By Country, 2000 & 2014 (USD)
Table 78 Asia: Vaccines Market, By Country, 2015-2022 (USD Million)
Table 79 Asia: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 80 Asia: Vaccines Market, By Type, 2015-2022 (USD Million)
Table 81 Asia: Vaccines Market, By Disease Indication, 2015-2022 (USD Million)
Table 82 Asia: Vaccines Market, By Route of Administration, 2015-2022 (USD Million)
Table 83 Asia: Vaccines Market, By End-User, 2015-2022 (USD Million)
Table 84 Japan: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 85 China: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 86 India: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 87 Roa: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 88 Row: Vaccines Market, By Technology, 2015-2022 (USD Million)
Table 89 Row: Vaccines Market, By Type, 2015-2022 (USD Million)
Table 90 Row: Vaccines Market, By Disease Indication, 2015-2022 (USD Million)
Table 91 Row: Vaccines Market, By Route of Administration, 2015-2022 (USD Million)
Table 92 Row: Vaccines Market, By End-User, 2015-2022 (USD Million)

List of Figures
Figure 1 Vaccines Market Segmentation
Figure 2 Research Design
Figure 3 Key Data from Secondary Sources
Figure 4 Key Data from Primary Sources
Figure 5 Market Size Estimation: Bottom-Up Approach
Figure 6 Market Size Estimation: Top-Down Approach
Figure 7 Breakdown of Primary Interviews: By Company Type, Designation, And Region
Figure 8 Data Triangulation Methodology
Figure 9 Global Vaccines Market, By Technology, 2017-2022
Figure 10 Global Vaccines Market, By Type, 2017 Vs. 2022 (USD Billion)
Figure 11 Global Vaccines Market, By Disease Indication, 2017 Vs. 2022 (USD Billion)
Figure 12 Global Vaccines Market, By Route of Administration, 2017 Vs. 2022 (USD Billion)
Figure 13 Global Vaccines Market, By End-User, 2017 Vs. 2022 (USD Billion)
Figure 14 Geographical Snapshot of Global Vaccines Market
Figure 15 High Prevalence of Diseases And Rising Government And Non-Government Funding for Vaccine Development—Primary Growth Drivers for Global Vaccines Market
Figure 16 Monovalent Vaccines Segment to Register Highest CAGR, 2017-2022 (USD Billion)
Figure 17 Pediatrics Segment to Lead Global Vaccines Market in 2022 (USD Billion)
Figure 18 Conjugate Vaccines Segment to Hold Largest Share of Global Vaccines Market in 2017
Figure 19 Intramuscular And Subcutaneous Administration Segment to Record Highest CAGR, 2017-2022 (USD Billion)
Figure 20 U.S. to Dominate Global Vaccines Market in 2017
Figure 21 Vaccine Market: Drivers, Restraints, Opportunities, And Challenges
Figure 22 Major Investors in Global Vaccines Market
Figure 23 Vaccine Funding, By Investor, 2014
Figure 24 Gavi Vaccine Funding, By Type of Investor, 2014
Figure 25 Gavi Forecast Vaccine Expenditure, By Disease, 2016-2020
Figure 26 Regulatory Approval Process for Vaccines
Figure 27 R&D Funding for Hiv Preventive Vaccines, By Investor, 2014
Figure 28 Conjugate Vaccines Segment to Lead Global Vaccine Market, By Technology, 2017-2022 (USD Million)
Figure 29 Monovalent Vaccines Segment to Lead Global Vaccines Market, By Type, 2017-2022 (USD Million)
Figure 30 Pneumococcal Disease Segment to Lead Global Vaccines Market, By Disease Indication, 2017-2022 (USD Million)
Figure 31 Global Vaccines Market for Dengue, 2015-2022 (USD Million)
Figure 32 Intramuscular And Subcutaneous Administration Segment to Lead Global Vaccines Market, By Route of Administration, 2017-2022 (USD Million)
Figure 33 Pediatrics End-User Segment to Lead Global Vaccines Market, By End-User, 2017-2022 (USD Million)
Figure 34 North America: Vaccines Market Snapshot, 2017
Figure 35 Europe: Vaccines Market Snapshot, 2017
Figure 36 Asia: Vaccines Market Snapshot, 2017
Figure 37 Row: Vaccines Market Snapshot, 2017
Figure 38 Vaccines Market Share Analysis, By Key Player, 2016
Figure 39 Vaccines Market (Global) Competitive Leadership Mapping, 2017
Figure 40 Pfizer, Inc.: Company Snapshot
Figure 41 Glaxosmithkline Plc.: Company Snapshot
Figure 42 Merck & Co., Inc.: Company Snapshot
Figure 43 Sanofi Pasteur Sa: Company Snapshot
Figure 44 Csl Limited: Company Snapshot
Figure 45 Emergent Biosolutions: Company Snapshot
Figure 46 Johnson & Johnson: Company Snapshot
Figure 47 Astrazeneca: Company Snapshot
Figure 48 Astellas Pharma, Inc.: Company Snapshot
Figure 49 Bavarian Nordic: Company Snapshot
Figure 50 Mitsubishi Tanabe Pharma Corporation: Company Snapshot
Figure 51 Daiichi Sankyo Company, Limited: Company Snapshot
Figure 52 Panacea Biotec: Company Snapshot (2016)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Astellas Pharma, Inc.
  • Bavarian Nordic
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Emergent Biosolutions, Inc.
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Medimmune, Llc (A Subsidiary of Astrazeneca)
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Panacea Biotec
  • Pfizer, Inc.
  • Protein Sciences Corporation
  • Sanofi Pasteur Sa
  • Serum Institute of India
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll